Education
About Us
Working with TipRanks
Follow Us
IXICO PLC (GB:IXI)
LSE:IXI
IXI Stock Chart & Stats
11.75p
-0.75p(-6.25%)
At close: 4:00 PM EST
11.75p
-0.75p(-6.25%)
Day’s Range― - ―
52-Week Range7.35p - 15.00p
Previous CloseN/A
Volume22.18K
Average Volume (3M)123.87K
Market Cap
£8.22M
Enterprise Value4.87M
Total Cash (Recent Filing)£3.54M
Total Debt (Recent Filing)£179.00K
Price to Earnings (P/E)―
Beta1.00
Next Earnings
May 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding92,668,594
10 Day Avg. Volume82,815
30 Day Avg. Volume123,868
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.01
Price to Sales (P/S)1.81
P/FCF Ratio-12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Order Book Growth And Revenue VisibilityAn expanding order book (GBP13.1m to GBP17.7m) and 15% revenue guidance materially increase mid‑term revenue visibility. A durable backlog supports capacity planning, steadier recurring project revenue and more efficient scaling of platform services, aiding progress to sustainable margins.
Niche AI Imaging & Biomarker PlatformIXICO’s specialized imaging analytics and AI biomarker platform in CNS creates technical and regulatory barriers that are hard to replicate. This domain expertise drives long‑cycle, mission‑critical contracts with sponsors, raising client stickiness, repeat business and structural pricing leverage over time.
Conservative Balance Sheet And Cash BufferA low‑leverage balance sheet with GBP3.5m cash and GBP11.7m net assets provides financial flexibility and runway. Conservatism in capital structure reduces refinancing risk, enables continued platform investment and partnerships, and supports the multi‑period path to the stated breakeven revenue level.
Bears Say
Consistent Net LossesPersistent net losses erode retained earnings and limit internal reinvestment. Ongoing unprofitability increases dependence on external capital, elevates dilution and constrains strategic flexibility; without durable margin improvements, losses can impede long‑term investment in platform and commercial scaling.
Negative Operating Cash Flow And Weak ConversionNegative operating cash flow and volatile free cash flow signal weak cash conversion despite revenue gains. Poor conversion undermines the company’s ability to self‑fund working capital and R&D for long clinical cycles, increasing execution risk and reliance on external financing over multiple quarters.
EBITDA Loss And Breakeven DependencyAn EBITDA loss of GBP1.3m and a stated breakeven target at GBP9.5m highlight material operating leverage required for profitability. Achieving that revenue threshold depends on sustained order conversion, margin recovery and cost control; failure to scale or improve gross margins prolongs loss absorption.
IXICO plc News
IXI FAQ
What was IXICO PLC’s price range in the past 12 months?
IXICO PLC lowest share price was 7.35p and its highest was 15.00p in the past 12 months.
What is IXICO PLC’s market cap?
IXICO PLC’s market cap is £8.22M.
When is IXICO PLC’s upcoming earnings report date?
IXICO PLC’s upcoming earnings report date is May 26, 2026 which is in 96 days.
How were IXICO PLC’s earnings last quarter?
IXICO PLC released its earnings results on Dec 09, 2025. The company reported -0.008p earnings per share for the quarter, missing the consensus estimate of N/A by -0.008p.
Is IXICO PLC overvalued?
According to Wall Street analysts IXICO PLC’s price is currently Overvalued.
Does IXICO PLC pay dividends?
IXICO PLC does not currently pay dividends.
What is IXICO PLC’s EPS estimate?
IXICO PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IXICO PLC have?
IXICO PLC has 92,668,594 shares outstanding.
What happened to IXICO PLC’s price movement after its last earnings report?
IXICO PLC reported an EPS of -0.008p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.953%.
Which hedge fund is a major shareholder of IXICO PLC?
Currently, no hedge funds are holding shares in GB:IXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IXICO PLC
IXICO plc (IXI) is a leading analytics and technology company that specializes in the provision of imaging and data analytics services in the healthcare sector, particularly for clinical trials and neurological diseases. The company operates primarily in the pharmaceutical and biotechnology industries, offering core services that include advanced imaging analysis, data management, and the interpretation of clinical data to support drug development and regulatory submissions.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Physiomics
―
Open Orphan Plc
―
Aptamer Group Plc
―